课题基金 / 基金详情

Therapeutic Use of Inter-alpha Inhibitor in Sepsis

Therapeutic Use of Inter-alpha Inhibitor in Sepsis
Inter-α抑制剂在脓毒症中的治疗用途
批准号:
6486378
负责人:
YOW-PIN LIM
金额:
$14.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-01 至 2003-03-31

项目摘要

项目成果

YOW-PIN LIM的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary goal of this proposed research is targeted towards demonstrating the commercial utilization of human plasma derived inter- alpha inhibitor proteins (IaIp) an effective therapy of sepsis. IaIp are serine protease inhibitors found normally at high levels in human plasma. The fact that no person with complete absence of IaIp has ever been detected suggests an essential physiological role for these proteins. In patients with severe sepsis, the plasma level of IaIp decrease significantly and the decrease correlates with mortality. We propose that administration of IaIp to restore the imbalance between these natural protective inhibitors and destructive proteases will prevent organ injuries and ultimately reduce sepsis related mortality. Our preliminary animal studies in a sepsis rat model of cecal ligation and puncture (CLP) have demonstrated the beneficial effects of IaIp in maintaining hemodynamic stability, preventing organ injury, and improving survival during sepsis. In this study, we propose to optimize a protocol for purification of IaIp from human crude plasma and to evaluate and confirm the beneficial effects of the purified IaIp in the CLP rat model. The ultimate goal of these studies is to develop a novel plasma derived therapeutic that is safe and effective for sepsis. PROPOSED COMMERCIAL APPLICATIONS: There is a serious unmet medical need for more than 1.5 million people worldwide annually who suffer from sepsis. Since there are currently no agents effective for sepsis, treatment is limited to antibiotic and supportive therapy. The magnitude of the need for an effective novel therapeutic agent in reducing sepsis mortality and morbidity is immense and it creates an enormous market potential estimated at $10-25 billion/year in the US alone. Inter-alpha inhibitor proteins appear to be an effective therapeutic agent of sepsis. The proposed study is expected to lead to the development of novel human plasma derived protein that is safe and effective for sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
  • 批准号:
    10822492
  • 项目类别:
  • 资助金额:
    $37.83万
  • 财政年份:
    2023
  • 负责人:
    YOW-PIN LIM
  • 依托单位:
Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis
  • 批准号:
    9925748
  • 项目类别:
  • 资助金额:
    $86.25万
  • 财政年份:
    2019
  • 负责人:
    YOW-PIN LIM
  • 依托单位:
Therapeutic Role of Inter-alpha Inhibitors in Wound Healing
  • 批准号:
    8834088
  • 项目类别:
  • 资助金额:
    $22.47万
  • 财政年份:
    2015
  • 负责人:
    YOW-PIN LIM
  • 依托单位:
Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury
  • 批准号:
    8715433
  • 项目类别:
  • 资助金额:
    $20.32万
  • 财政年份:
    2014
  • 负责人:
    YOW-PIN LIM
  • 依托单位:
海外基金